• J Curot, M Denuelle, T Busigny, G Barragan-Jason, M Kany, P Tall, F Marlat, N Fabre, and L Valton.
• Service de Neurologie et d'Explorations Fonctionnelles Neurologiques, Unité "Chirurgie de l'épilepsie", Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, 1 avenue du Pr Jean Poulhès TSA 50032, 31059 Toulouse, France; CERCO - Centre de Recherche Cerveau et Cognition UMR 5549 - CNRS (Centre National de la Recherche Scientifique), Pavillon Baudot, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Place du Dr Baylac, 31059 Toulouse, France. Electronic address: curot@cerco.ups-tlse.fr.
• Seizure. 2014 Feb 1; 23 (2): 122-8.

PurposeThe Wada test is still the gold standard procedure to predict language and memory deficits before temporal lobe epilepsy surgery. As amobarbital was no longer available, our aim was to validate propofol as an alternative.MethodWe retrospectively studied 47 patients who underwent a bilateral intracarotid procedure, performed with amobarbital (18), or propofol (29), between 2000 and 2010 during the preoperative evaluation of temporal lobe epilepsy.ResultsThe number of patients experiencing an adverse event (mostly transient disturbance of consciousness or benign ocular symptoms) during both injections did not differ significantly between amobarbital and propofol. Hemispheric dominance was successfully determined in 96.5% patients with propofol vs. 94.4% with amobarbital for language, and in 72.4% under propofol vs. 77.7% under amobarbital for memory with no significant difference between groups.ConclusionPropofol can be used for the Wada test with an efficacy and safety comparable to amobarbital.Copyright © 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

36 keywords...

hide…